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Genome-wide redistribution of MeCP2 
in dorsal root ganglia after peripheral nerve 
injury
Melissa T. Manners1, Adam Ertel2, Yuzhen Tian1 and Seena K. Ajit1* 
Abstract 
Background: Methyl-CpG-binding protein 2 (MeCP2), a protein with affinity for methylated cytosines, is crucial for 
neuronal development and function. MeCP2 regulates gene expression through activation, repression and chromatin 
remodeling. Mutations in MeCP2 cause Rett syndrome, and these patients display impaired nociception. We observed 
an increase in MeCP2 expression in mouse dorsal root ganglia (DRG) after peripheral nerve injury. The functional 
implication of increased MeCP2 is largely unknown. To identify regions of the genome bound by MeCP2 in the DRG 
and the changes induced by nerve injury, a chromatin immunoprecipitation of MeCP2 followed by sequencing (ChIP-
seq) was performed 4 weeks after spared nerve injury (SNI).
Results: While the number of binding sites across the genome remained similar in the SNI model and sham control, 
SNI induced the redistribution of MeCP2 to transcriptionally relevant regions. To determine how differential binding 
of MeCP2 can affect gene expression in the DRG, we investigated mmu-miR-126, a microRNA locus that had enriched 
MeCP2 binding in the SNI model. Enriched MeCP2 binding to miR-126 locus after nerve injury repressed miR-126 
expression, and this was not mediated by alterations in methylation pattern at the miR-126 locus. Downregulation 
of miR-126 resulted in the upregulation of its two target genes Dnmt1 and Vegfa in Neuro 2A cells and in SNI model 
compared to control. These target genes were significantly downregulated in Mecp2-null mice compared to wild-
type littermates, indicating a regulatory role for MeCP2 in activating Dnmt1 and Vegfa expression. Intrathecal delivery 
of miR-126 was not sufficient to reverse nerve injury-induced mechanical and thermal hypersensitivity, but decreased 
Dnmt1 and Vegfa expression in the DRG.
Conclusions: Our study shows a regulatory role for MeCP2 in that changes in global redistribution can result in direct 
and indirect modulation of gene expression in the DRG. Alterations in genome-wide binding of MeCP2 therefore 
provide a molecular basis for a better understanding of epigenetic regulation-induced molecular changes underlying 
nerve injury.
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Background
Epigenetic modifications resulting from DNA methyla-
tion play a critical role in cellular differentiation, devel-
opment [1] and may contribute to disease including 
peripheral and central pain sensation and processing [2]. 
DNA methylation is mediated by DNA methyltransferase 
(DNMT) catalyzing the transfer of a methyl group onto 
the 5′ position of cytosine. MeCP2 can decipher meth-
ylation patterns across the genome before binding to 
methylated DNA [1] and can mediate downstream 
transcriptional changes of a large number of genes [3]. 
Depending on its interacting protein partners and target 
genes, MeCP2 can act as either an activator or repressor 
[4]. MeCP2 can also play a role in dampening genome-
wide transcriptional noise in a DNA methylation-
dependent manner [5]. Mutations in MECP2 result in 
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the neurodevelopmental disorder Rett syndrome (RTT) 
[6]. Among the many symptoms associated with RTT, 
alterations in pain sensitivity are reported to be as high 
as 75  % [7]. Reduced sensitivity has been observed in 
mouse models with RTT and autism-associated muta-
tions [8–11]. The observations from RTT patients and 
MeCP2-mutant mice indicate that MeCP2 contributes 
either directly or indirectly to reduced pain sensitivity.
Our previous study has shown that MeCP2 expression 
was altered in mouse dorsal root ganglia (DRG) following 
spared nerve injury (SNI). While we observed upregula-
tion of MeCP2 protein 4  weeks post-surgery [10], oth-
ers have reported downregulation at earlier time points 
and in subsets of damaged neurons in the DRG [11, 12]. 
MeCP2 has previously been linked to inflammatory pain. 
Inflammatory stimulus was shown to increase phospho-
rylation of MeCP2 in lamina I neurons in the dorsal horn, 
resulting in its dissociation from the genome, thereby 
alleviating repression of genes linked to pain [13]. MeCP2 
has also been associated with central mechanisms of pain 
through regulation of a transcriptional repressor, histone 
dimethyltransferase G9a, resulting in increased expres-
sion of brain-derived neurotrophic factor [14].
MeCP2 is highly expressed in neurons and glia [5]. The 
dynamic expression of MeCP2 in the DRG after nerve 
injury [10] suggests a role for MeCP2 in pain modulation 
through transcriptional regulation. DRG are major players 
responsible for conveying noxious stimuli from the periph-
ery to the central nervous system. MeCP2 is predominantly 
a nuclear protein and cell bodies of nociceptive sensory 
neurons are located in DRG, with two axonal branches pro-
jecting to the periphery and to the dorsal horn of the spinal 
cord. Genome-wide studies investigating MeCP2 binding 
patterns have been conducted in neurons, astrocytes and 
different regions of the brain [5, 15–17]. To investigate the 
role of MeCP2 in mediating nociception, and to determine 
changes in MeCP2 binding patterns after nerve injury, 
we performed chromatin immunoprecipitation followed 
by massively parallel sequencing (ChIP-seq) in mouse 
DRG 4  weeks after SNI surgery. We observed a genome-
wide redistribution of MeCP2 binding and evaluated how 
changes in binding patterns directly and indirectly regulate 
genes that contribute to the pathology of pain.
Methods
Animal model of neuropathic pain
The care and use of all mice were approved by the Institu-
tional Animal Care & Use Committee of Drexel Univer-
sity College of Medicine. The SNI model was generated 
using 8-week-old C57BL/6 male mice (Taconic) as previ-
ously described [18, 19]. Briefly, mice were anesthetized 
with isoflurane during surgery. The common peroneal 
and tibial nerves of the left paw were ligated, and 2–4 mm 
of the nerve was sectioned and removed distal to ligation. 
Sham mice underwent the same surgical procedures as 
the SNI group without ligation and sectioning. Develop-
ment of mechanical hypersensitivity was assessed using 
von Frey filaments [18]. L4, L5 and L6 DRG on the ipsi-
lateral side of surgery were collected 4  weeks post-SNI 
surgery at 12 weeks of age.
Mecp2‑null mice
DRG from approximately 12-week-old male hemizygous 
Mecp2-null (Mecp2−/y) mice and wild-type littermates 
(Mecp2+/y) were collected for molecular characteriza-
tion [20]. These mice do not have detectable Mecp2 gene 
product and were used to study gene expression in the 
absence of MeCP2.
Chromatin immunoprecipitation (ChIP) of MeCP2
ChIP was performed using protocols adapted from Cova-
ris truChIP chromatin shearing kit tissue SDS and Mil-
lipore magna ChIP G tissue kits. Ipsilateral L4, L5 and L6 
DRG were collected 4 weeks after SNI or sham surgery. 
DRG were pooled from ten mice per sample, in dupli-
cate. Samples were washed 3 times in phosphate-buffered 
saline (PBS) containing protease inhibitors (PI). Chro-
matin was crosslinked to DNA using 1 % methanol-free 
formaldehyde and incubated at room temperature for 
5  min with rotation. Samples were then incubated with 
Covaris quenching buffer for 5 min at room temperature 
with rotation to quench the formaldehyde crosslinking. 
Samples were washed 3 times for 5  min with PBS con-
taining PI. Tissue samples were resuspended in Covaris 
lysis buffer containing PI, incubated on ice for 10  min 
and homogenized by pipetting. After 10-min incubation 
on ice, nuclei were pelleted at 1700×g for 5 min at 4 °C. 
Samples were washed using 1  ml Covaris wash buffer, 
pellets resuspended in 130 µl Covaris SDS shearing buffer 
containing PI and incubated on ice for 10  min. Chro-
matin was sheared using the Covaris M220. Insoluble 
material was pelleted by centrifugation at 10,000×g for 
5  min. Five microliters of the supernatant was removed 
for input samples. To each sample, 20  µl of Protein G 
magnetic beads and 5  µl rabbit anti-MeCP2 antibody 
[21, 22] or 5  µl rabbit serum was added and incubated 
overnight at 4 °C with rotation. Beads were pelleted with 
a magnetic separator, washed and resuspended in Mil-
lipore elution buffer containing proteinase K, followed 
by incubations at 62 °C overnight, and 95 °C for 10 min. 
Supernatant was used for DNA purification according to 
manufacturer’s instructions. For identification of MeCP2 
binding to miR-126, PCR was performed using DNA iso-
lated from DRG. Primer sequences used were: Forward: 
TATTTTGAAGAGGTTTTTGGAAGG and Reverse: 
CCAAAACACACAACTAACTAAAAACAA.
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Sequence alignment and filtering
Single-end 50-base reads were generated on the Applied 
Biosystems (AB) SOLiD 5500xl platform. Reads were 
mapped to the mm10 genome using AB LifeScope 2.5.1 
software. Reads in each sample were filtered out based on 
their mapping quality, to eliminate poorly mapping reads 
and reads that may map to multiple places in the genome, 
and only reads MAPQ ≥  10 were used for peak calling 
and tag enrichment analysis. Samtools [23] merge was 
used to pool replicates for each IP condition, and sam-
tools rmdup was used to remove duplicate reads so that 
only unique tags were used for peak calling.
Peak calling
The HOMER (Hypergeometric Optimization of Motif 
EnRichment) suite [24] was used for peak calling on the 
sham and SNI IP sequence libraries, using respective 
sham and SNI input libraries as control. HOMER ChIP-
seq tag directories were created from the set of unique 
mapped reads for each IP and input condition. HOMER 
peak calling (findPeaks) was performed for both narrow 
peaks (-style factor) and broad peaks (-style histone). 
Visual review of the sequence tags in the Integrated 
Genomics Viewer (IGV) [25] was used to decide whether 
narrow or broad peaks were a better fit for MeCP2 bind-
ing patterns. The set of broad peaks was selected as the 
better representation of MeCP2 binding and used for 
subsequent annotation and interpretation. HOMER was 
also used to identify differential binding between sham 
and SNI, using the getDifferentialPeaks tool, with default 
settings to identify peaks with fourfold more tags in one 
condition versus the other, with p value less than 0.0001.
Annotation
The HOMER annotation database v5.4 for mouse was 
used in conjunction with the HOMER annotation tool 
(annotatePeaks) to identify the closest genomic feature 
to each peak, as well as enrichment statistics for genomic 
regions including promoters, exons, introns, intergenic 
regions. Annotation was performed on the set of all sham 
peaks, all SNI peaks, as well as differentially bound peaks 
in sham and SNI. The HOMER annotatePeaks tool was 
also used in mRNA and miRNA mode to analyze tag 
enrichment and peak locations with respect to all anno-
tated genes and miRNAs.
Cell culture and transfection
Neuro 2a cells obtained from American Type Culture 
Collection (ATCC) were maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10  % 
fetal bovine serum at 37  °C in 5 % CO2. For monitoring 
changes in endogenous Dnmt1 and Vegfa expression, 
cells were transfected with precursor miR-126 plasmid 
(GeneCopoeia) using X-tremeGENE HP DNA transfec-
tion reagent (Roche) for 72 h.
Quantitative RT‑PCR
RNA was purified from the following samples: Neuro 
2a cells, DRG collected from SNI model, sham control, 
Mecp2-null and wild-type littermate mice using the 
mirVana RNA isolation kit (Life technologies). cDNA 
synthesis and qRT-PCR for mRNA were performed 
as previously described [26]. The Assay ID for TaqMan 
primer probes used were Mm00599780_g1 (Dnmt1) and 
Mm00437306_m1 (Vegfa). Gapdh was used as a normal-
izer. cDNA synthesis for miR-126 and detection was con-
ducted using TaqMan microRNA assay (Assay ID 00451, 
Applied Biosystems). U6 was used for normalization.
Western blot
Protein from Neuro 2a cells or DRG was isolated using 
radioimmunoprecipitation assay buffer (Thermo Scientific). 
For Western blotting, 2 µg protein lysate from DRG or 10 µg 
from cell pellets was resolved by a 4–12 % SDS-PAGE gel, 
transferred to nitrocellulose membrane. The membranes 
were probed with 1:500 dilution of Dnmt1 (D63A6) XP 
antibody #5032 (Cell Signaling) or 1:1000 Vegfa antibody 
(Abcam ab51745) overnight at 4  °C. Chemiluminescence 
was detected using FluorChem M System (Protein Simple). 
The membrane was also probed with 1:1000 beta tubulin 
(9F3) antibody #2128 (Cell Signaling) as a loading control. 
Quantification was done using UN-SCAN-IT software, and 
Dnmt1 and Vegfa expression was normalized to beta tubulin.
Immunocytochemistry
Neuro 2a cells grown on 12-mm glass coverslips were 
transfected with miRNA precursor plasmids with GFP 
using X-tremeGENE HP DNA transfection reagent for 
72 h. Cells were fixed in 4 % formaldehyde and blocked 
with 10 % normal goat serum followed by a 3-h incuba-
tion in 1:500 anti-Dnmt1 antibody (mentioned above). 
Anti-Rabbit-IgG Atto 647N secondary antibody (Sigma) 
was used for detection of Dnmt1. Coverslips were 
mounted using Vectashield mounting medium with 
DAPI (Vector Laboratories). Images were acquired using 
the 60× objective on the Olympus FV1000 confocal 
microscope and Fluoview FV10-ASW software. Trans-
fected (GFP positive) and untransfected (GFP negative) 
cells were compared.
Intrathecal catheter implantation and miRNA injection
miRNA administration protocol was adapted from previ-
ous report of intrathecal miRNA delivery [27]. To admin-
ister miRNA mimics, a polyurethane catheter (25G, 5.5 cm 
long, SAI infusion) was placed into the intrathecal space of 
the lumber L4–L5 vertebrae under isoflurane anesthesia. 
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The catheter was stereotactically secured under the skin 
and occluded between injections. A custom miRCURY 
(Exiqon) miR-126 mimic containing a 5′ cholesterol tag 
and 3′ fluorescein label was injected at 2 nmol concentra-
tion with 4  µl iFECT transfection reagent (Neuromics). 
A total of 6 µl was delivered into the catheter connection 
juncture using a 25G blunt end needle on a Hamilton 
syringe. The catheter was then flushed with 7 µl sterile PBS 
to ensure miRNA reached the intrathecal space.
Bisulfite sequencing and analysis of CpG sites in miR‑126 
locus and putative promoter
To analyze the methylation status of CpG dinucleotides 
in the miR-126 locus, L4, L5 and L6 DRG were collected 
from three SNI or three sham control mice 4 weeks after 
surgery. Mouse genomic DNA was isolated using Gen-
Elute mammalian genomic DNA minipreps kit (Sigma 
Aldrich) and subjected to bisulfite conversion using 
the Epitect fast DNA bisulfite kit (Qiagen). The 72-bp 
fragment of interest was amplified using the following 
primer pairs designed with MethPrimer software [28]: 
Forward: TATTTTGAAGAGGTTTTTGGAAGG and 
Reverse: CCAAAACACACAACTAACTAAAAACAA. 
The 140-bp fragment within the promoter of Egfl7 was 
amplified using the following primer pairs: Forward: 
GGGAAGGGTTTATTTTAGTTTTGAT and Reverse: 
ATCTACTACCCAAAATCCCTCCTAA.
Gene ontology analysis
HOMER peaks for sham and SNI datasets were filtered 
to include only peaks within ±2 kb of gene transcription 
start sites. Functional analysis was performed on the genes 
associated with these peaks by testing for gene ontology 
(GO) term enrichment using ToppGene [29]. Functional 
analysis was repeated for genes associated with differential 
bound peaks around the promoter (±2  kb) using the set 
of peaks identified as fourfold higher and sham (fourfold 
down in SNI) and the set of peaks identified as fourfold 
higher in SNI. Additionally, a tag-based analysis was per-
formed to identify transcribed gene regions with differen-
tial tag enrichment, producing a set of genes with fourfold 
higher tag enrichment in sham (fourfold down in SNI) and 
a set of genes with fourfold higher tag enrichment in SNI 
(fourfold up in SNI) with a differential enrichment p value 
of 0.01. Functional analysis for enriched GO terms was 
then performed on the resulting gene sets.
Statistical methods
For statistical analysis, mean values with standard error 
are shown; p values were determined using t tests with 
paired or unpaired samples, and significance was set at 
p < 0.05.
Results
MeCP2–DNA binding profiles
To determine nerve injury-induced changes in MeCP2-
bound chromatin, we conducted ChIP-seq in the DRG 
from SNI model and sham control mice. Generation 
of  the SNI model, confirmation of hypersensitivity and 
DRG collection 4  weeks post-surgery have been previ-
ously described [10]. ChIP-seq was conducted on DRG 
pooled from ten mice per sample. We determined that 
MeCP2 binding occurred broadly across the genome, 
as previously reported [5, 17]. Enriched binding was 
observed in promoter regions and gene bodies for both 
protein-coding and noncoding genes in SNI and sham 
control DRG (Fig.  1a–c). Table  1 shows the enriched 
binding for both coding and noncoding regions in SNI 
and sham control DRG and the p values for Fig. 1c. The 
number of unique sham IP tags was 2,178,607; unique 
sham input tags were 20,020,088, and the total sham 
peaks were 85,903. For SNI, the unique SNI IP tags were 
2,982,156, unique SNI input tags were 12,917,142, and 
total SNI peaks were 88,755. Comparison of MeCP2-
bound sequences at single base resolution indicates 
both distinct and common MeCP2 binding sites to 
regions encoding mRNAs in SNI and sham DRG sam-
ples (Fig. 1d). GO analysis of our ChIP-seq results (top 10 
enriched GO terms with p < 0.01 shown in Table 2, com-
plete list shown in Additional file  1: Table S1) indicates 
that MeCP2 binding occurs at the promoter of genes 
with neuronal function, ion channel activity and cellular 
membrane functions. These results closely correspond 
with previous reports of genes repressed by MeCP2 iden-
tified in the brain [16].  
Genome‑wide redistribution of MeCP2 binding in the DRG 
after nerve injury
Comparative analysis of enriched peaks in SNI versus 
sham was done to elucidate nerve injury-induced dif-
ferences in genome-wide MeCP2 binding. A redistribu-
tion of MeCP2 binding in SNI as indicated by increased 
enrichment within transcribed regions is shown in 
Fig.  2a, b. Sham peaks bound fourfold higher than in 
SNI (i.e., 4× as many tags) was 56,423; SNI peaks 
bound fourfold higher than in sham (i.e., 4× as many 
tags) was 17,686. Table 3 shows ten genes with enriched 
MeCP2 binding in the promoter and in the gene bod-
ies that have a fourfold increase or decrease (log2 fold 
change) between sham and SNI, with p  <  0.001. Dis-
tinct binding patterns of MeCP2 in SNI could therefore 
lead to alterations in the genome, which in turn can 
mediate gene expression changes ensuing nerve injury. 
Complete ChIP-seq data are shown in Additional file 2: 
Table S2.
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Enriched MeCP2 binding to miRNAs
We then investigated changes in MeCP2 binding 
to miRNAs after nerve injury. While miRNA-tran-
scribed regions represent a much smaller fraction of 
the genome compared to protein-coding genes, our 
analysis highlighted a small number of miRNA loci 
with distinct MeCP2 binding. A subsequent analysis 
of MeCP2-bound sequence tags indicated that miRNA 
regions were enriched for MeCP2 binding, and this 
enrichment was observed in the SNI model (Fig.  3a). 
However, within several miRNA regions identified as 
MeCP2-enriched, binding was detected in only one 
condition, sham or SNI, indicating different regula-
tory profiles in SNI versus sham. Our analysis showed 
that 242 peaks were within 2  kb of miRNA regions in 
sham and 271 peaks were within 2 kb of miRNA regions 
in SNI. Based strictly on tag locations, there were 158 
tags overlapping 76 miRNA regions in sham, and 297 
tags overlapping 140 regions in SNI. Thus, a larger pro-
portion of tags overlapped a larger number of miRNA 
regions in SNI compared to sham. However, only a 
minority of occupied miRNAs in SNI met the fourfold 
cutoff for differential binding relative to sham. The miR-
NAs most enriched for MeCP2 binding, including 14 
miRNAs with increased MeCP2 binding and 21 miR-
NAs with decreased binding in the SNI model relative 
to sham, are shown in Fig. 3b. Our analysis showed that 
miR-126 and miR-6340 had the largest fold enrichment 
for SNI and sham, respectively (Additional file  3: Fig. 
S1a and S1b). Since miR-126a and miR-126b had the 
largest fold enrichment in the SNI model, we confirmed 
MeCP2 binding to miR-126 locus by ChIP-PCR (Addi-
tional file 4: Fig. S2).
Fig. 1 Genome-wide MeCP2-DNA binding profile in the DRG from SNI and sham control mice. a–b Genomic distribution of peaks from ChIP-seq 
in the sham and SNI samples. c Enrichment of MeCP2 binding to genomic regions in the SNI and sham models. Enrichment in SNI and sham, and 
p values are shown in Table 1. d Common and unique broad peaks identified in regions encoding mRNAs in SNI and sham. ChIP-seq data were 
generated from two IP samples each, for SNI and sham. Each sample contained L4, L5 and L6 ipsilateral DRG obtained from ten mice each, 4 weeks 
after surgery. 3UTR 3′ untranslated region, 5UTR 5′ untranslated region, ncRNA noncoding RNA, Pseudo pseudo genes, rRNA ribosomal RNA, TTS 
transcription termination sites
Table 1 Enriched binding for  both coding and  noncod-
ing regions in SNI and sham control DRG and the p values 
for Fig. 1c
Annotation Sham SNI
Log2 enrich‑
ment
p value Log2 enrich‑
ment
p value
3UTR 0.775 0 0.997 0
ncRNA 0.699 1.48699E−08 0.815 2.2653E−12
TTS 0.559 0 0.733 0
Pseudo 0.209 0.52247426 0.92 0.000232852
Exon 2.046 0 1.883 0
Intron 0.185 0 0.308 0
Intergenic −0.278 0 −0.352 0
Promoter 1.136 0 0.655 0
5UTR 1.958 0 1.196 0
rRNA 2.494 0.050658031 2.446 0.056264625
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Upon confirmation, we pursued further characteriza-
tion and significance of enriched MeCP2 binding to the 
miR-126.
miR‑126 locus has enriched MeCP2 binding in SNI
The peak profile for miR-126 locus from ChIP-seq shows 
enrichment for MeCP2 binding over input control and 
sham samples (Fig.  4a). We observed an enrichment of 
MeCP2 binding to miR-126 locus after nerve injury, with 
virtually no binding in the sham sample. This indicates 
that nerve injury induced an increase in MeCP2 bind-
ing to miR-126 locus, and hence, we further explored the 
functional consequences of this binding in the context of 
nerve injury-induced pain.
Methylation of miR‑126 locus
Cytosine methylation of CpG dinucleotides is recog-
nized as a crucial epigenetic modification. Since MeCP2 
is a methyl DNA binding protein, we wanted to investi-
gate whether increased MeCP2 binding to miR-126 locus 
Table 2 Gene ontology analysis of MeCP2 bound promoters
The top ten enriched gene ontology (GO) terms with p < 0.01 are listed for molecular function, biological process, and cellular component, respectively. GO analysis 
of our ChIP-seq results indicates that MeCP2 binding occurs at the promoter of genes with neuronal function, ion channel activity and cellular membrane functions. 
These results closely correspond with previous reports of genes repressed by MeCP2 in brain [16]
GO term p value q value FDR B&H Hit count in query list GO accession
Molecular function
 RNA polymerase II transcription factor activity, sequence-
specific DNA binding
2.09E−09 6.41E−06 214 GO:0000981
 Transcriptional activator activity, RNA polymerase II transcrip-
tion regulatory region sequence-specific binding
7.30E−08 1.12E−04 125 GO:0001228
 Transcription factor activity, RNA polymerase II core promoter 
proximal region sequence-specific binding
1.13E−07 1.16E−04 126 GO:0000982
 Enzyme binding 3.44E−06 2.12E−03 500 GO:0019899
 Regulatory region DNA binding 3.82E−06 2.12E−03 247 GO:0000975
 Transcription regulatory region DNA binding 4.16E−06 2.12E−03 246 GO:0044212
 Regulatory region nucleic acid binding 5.08E−06 2.23E−03 247 GO:0001067
 Receptor binding 1.94E−05 5.74E−03 427 GO:0005102
 Sequence-specific double-stranded DNA binding 2.10E−05 5.74E−03 211 GO:1990837
 Double-stranded DNA binding 2.15E−05 5.74E−03 233 GO:0003690
Biological process
 Tissue development 7.05E−18 7.67E−14 595 GO:0009888
 Skeletal system development 5.71E−17 3.11E−13 203 GO:0001501
 Organ morphogenesis 9.09E−16 3.30E−12 345 GO:0009887
 Regulation of multicellular organismal 3.00E−15 7.71E−12 541 GO:2000026
 Regulation of cell differentiation 3.54E−15 7.71E−12 509 GO:0045595
 Regulation of nervous system development 6.60E−15 1.20E−11 292 GO:0051960
 Neurogenesis 8.78E−15 1.37E−11 557 GO:0022008
 Regulation of cell development 4.71E−14 6.42E−11 316 GO:0060284
 Generation of neurons 1.11E−13 1.34E−10 528 GO:0048699
 Positive regulation of cell differentiation 3.12E−13 3.28E−10 309 GO:0045597
Cellular component
 Neuron projection 2.19E−08 2.77E−05 333 GO:0043005
 Neuron part 1.99E−07 1.26E−04 409 GO:0097458
 Somatodendritic compartment 1.93E−06 8.17E−04 246 GO:0036477
 Cell body 8.24E−06 1.86E−03 197 GO:0044297
 Integral component of plasma membrane 8.41E−06 1.86E−03 427 GO:0005887
 Neuronal cell body 8.81E−06 1.86E−03 178 GO:0043025
 Anchoring junction 1.21E−05 2.19E−03 152 GO:0070161
 Intrinsic component of plasma membrane 1.66E−05 2.63E−03 440 GO:0031226
 Potassium channel complex 2.10E−05 2.96E−03 38 GO:0034705
 Adherens junction 3.00E−05 3.80E−03 145 GO:0005912
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observed in the DRG from  the SNI model was due to 
changes in methylation pattern. Our analysis of the 72-bp 
sequence of premiR-126 locus revealed the presence of 
6 CpG sites. To evaluate whether SNI surgery caused 
alterations in the methylation status of premiR-126 locus, 
we performed bisulfite sequencing of DRG genomic DNA 
obtained from SNI and sham control mice 4 weeks after 
surgery. Our analysis of the methylation status showed 
Fig. 2 Redistribution of MeCP2 binding in the DRG after nerve injury. a Genome-wide distribution of enriched peaks representing putative MeCP2 
binding sites that are at least fourfold higher in the SNI model compared to sham control. b Genomic redistribution of MeCP2 binding determined 
by enriched peaks in the SNI, and sham model indicates increased MeCP2 binding to transcriptionally relevant regions and noncoding RNAs. 3UTR 
3′ untranslated region, 5UTR 5′ untranslated region, ncRNA noncoding RNA, Pseudo pseudo genes, rRNA ribosomal RNA, TTS transcription termina-
tion sites; NS not significant *p value <1 × 10−3
Table 3 Top ten MeCP2-enriched promoters and  genes identified by  ChIP-seq in  the DRG from  SNI model compared 
to sham control
Nearest refseq Gene name Gene description Tag count p value
Sham SNI
Promoters with enriched MeCP2 binding
 NM_021478 Tulp1 Tubby like protein 1 0 30 2.85E−06
 NM_027398 Kcnip1 Kv channel-interacting protein 1 0 19 0.000195
 NM_170757 Ccdc186 Coiled-coil domain containing 186 0 16 0.000629
 NM_001034898 Ms4a15 Membrane-spanning 4-domains, subfamily A, member 15 0 25 1.92E−05
 NR_033168 Snora28 Small nucleolar RNA, H/ACA box 28 0 26 1.31E−05
 NM_001113379 Lrrc32 Leucine rich repeat containing 32 0 25 1.92E−05
 NM_011305 Rxra Retinoid X receptor alpha 0 15 0.000932
 NM_018820 Sertad1 SERTA domain containing 1 0 17 0.000425
 NM_001011525 Olfr1415 Olfactory receptor 1415 0 16 0.000629
 NM_133759 Zbtb3 Zinc finger and BTB domain containing 3 0 25 1.92E−05
Gene bodies with enriched MeCP2 binding
 NM_001001807 Olfr279 Olfactory receptor 279 0 21 8.97E−05
 NM_011540 Tcap Titin-cap 0 16 0.000629
 NM_011971 Psmb3 Proteasome (prosome, macropain) subunit, beta type 3 0 19 0.000195
 NM_198414 Paqr9 Progestin and adipoQ receptor family member IX 0 20 0.000132
 NM_133668 Slc25a3 Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3 0 15 0.000932
 NM_001160356 Uqcc3 Ubiquinol-cytochrome c reductase complex assembly factor 3 0 15 0.000932
 NM_001190356 Gm4832 Predicted gene 4832 0 15 0.000932
 NM_133759 Zbtb3 Zinc finger and BTB domain containing 3 0 25 1.92E−05
 NM_009296 Supt4a Suppressor of Ty 4A 0 20 0.000132
 NM_009756 Bmp10 Bone morphogenetic protein 10 0 18 0.000288
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that all 6 CpG sites were methylated in both SNI and 
sham samples (Fig.  4b). This identical methylation pat-
terns in SNI and sham control mice indicates that nerve 
injury did not alter the methylation status of premiR-126 
locus. Since there was an increase in MeCP2 bound to 
premiR-126 after nerve injury, we postulate that MeCP2 
redistribution throughout the genome and the specific 
enrichment at miR-126 could be induced by alterations 
in the availability of the genome for MeCP2 binding, after 
nerve injury. The location of miR-126 is within the Egfl7 
gene, and the expression levels of miR-126 correlate with 
expression of Egfl7 [30]. We therefore investigated meth-
ylation at the Egfl7 promoter which had a CpG island. 
Bisulfite sequencing at the putative promoter of miR-126 
showed that there were no changes in CpG methylation 
(data not shown).
miR‑126 regulates expression of Dnmt1 and Vegfa in Neuro 
2a cells
The Neuro 2a mouse neuroblastoma cell line was used to 
investigate regulation of target gene expression by miR-
126. Previous studies have demonstrated direct binding 
of miR-126 to the 3′ untranslated region (UTR) of vas-
cular endothelial growth factor (Vegfa) [31] and DNA 
methyltransferase 1 (Dnmt1) [32]. Neuro 2a cells were 
transfected with miR-126 precursor plasmid, or scram-
bled miRNA control, expressing GFP. We observed a 
decrease in mRNA (Fig.  5a) and protein levels (Fig.  5b) 
of Dnmt1 and Vegfa 72  h after miR-126 transfec-
tion. We also show that miR-126-transfected cells have 
decreased Dnmt1 expression compared to untransfected 
cells (Fig.  5c). Based on the decrease in both transcript 
and protein levels, we conclude that miR-126 regulates 
expression of both Dnmt1 and Vegfa through degrada-
tion of mRNA.
Repression of miR‑126 and upregulation of its target genes 
in the SNI model
We next sought to determine the consequence of 
increased MeCP2 binding to miR-126 locus in the DRG 
after nerve injury. There was a significant decrease of 
miR-126 in the DRG after SNI (Fig.  6a). This indicates 
that increased binding of MeCP2 represses transcription 
of miR-126. We hypothesized that reduced levels of miR-
126 would result in increased expression of miR-126 tar-
get genes in the DRG. An increase in Dnmt1 and Vegfa 
transcripts was observed in the SNI model (Fig.  6b, c). 
Western blot analysis confirmed an increase in Dnmt1 
protein (Fig. 6d). However, we did not observe significant 
changes in Vegfa protein in the DRG (Fig. 6e). Previous 
studies have shown that peripheral nerve injury leads 
to upregulation of Vegfa in accumulating neutrophils 
and macrophages in the peripheral nerve [33]. Vegfa is 
a secreted protein; therefore, protein expression in the 
DRG may not reflect miR-126-mediated regulation of 
Vegfa. Based on our in vitro data and reduced transcript 
levels of both target genes in the DRG after SNI, we con-
clude that downregulation of miR-126 levels resulting 
from MeCP2 binding can contribute to the upregulation 
of Dnmt1 and Vegfa after nerve injury.
Expression of miR‑126 and target genes Dnmt1 and Vegfa 
in DRG from Mecp2‑null mice
To further confirm the regulatory role of MeCP2 on 
miR-126 expression, we obtained DRG from Mecp2-
null mice. We assessed miR-126 levels in Mecp2-null 
mice and found that there were no significant differ-
ences compared to wild-type littermates (Fig.  7a). This 
finding along with our observation from the SNI model 
indicates that MeCP2 does not regulate expression of 
miR-126 under naïve conditions. However, there was 
increased MeCP2 binding to miR-126 upon nerve injury, 
resulting in miR-126 repression. Since miR-126 is a 
negative regulator of Dnmt1 and Vegfa, we wanted to 
investigate whether MeCP2 can also affect expression of 
these genes. Thus, we assessed mRNA levels of Dnmt1 
and Vegfa in the DRG of Mecp2-null mice to determine 
the regulatory role of MeCP2. These mice do not have 
detectable levels of MeCP2. Our qPCR results showed 
a downregulation of Dnmt1 (Fig. 7b) and Vegfa (Fig. 7c) 
in the DRG in the absence of MeCP2, suggesting that 
MeCP2 may directly or indirectly regulate the activation 
of these genes.
Fig. 3 Enriched MeCP2 binding to miRNAs in the SNI model. a 
miRNA tag enrichment is greater in the SNI model compared to sham 
control, suggesting altered MeCP2-mediated regulation of miRNAs 
after nerve injury p value 1.2 × 10−3. b miRNAs listed have at least 
fourfold tag enrichment in the SNI or sham model. miR-126 was the 
miRNA with the highest tag enrichment in the SNI model
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Overexpression of miR‑126 in vivo did not alter pain 
threshold but decreased target gene expression
We observed regulation of Dnmt1 and Vegfa by miR-126 
in Neuro 2a cells, and an inverse correlation in expression 
of miR-126 and its target genes in the DRG after nerve 
injury. To investigate whether upregulation of miR-126 can 
alter pain threshold in the  SNI model mice, we intrathe-
cally administered exogenous miR-126. An intrathecal 
catheter was implanted 4 weeks after SNI surgery, to allow 
for repeated administration of 2  nmol miR-126 or con-
trol miRNA. We did not observe a change in mechanical 
(Fig.  8a) or thermal (data not shown) hypersensitivity in 
these mice, after overexpressing miR-126. With the lack 
of efficacy in pain behavior studies, we wanted to confirm 
miR-126 delivery to the DRG and investigate changes in 
Vegfa and Dnmt1 expression. Over fivefold higher lev-
els of miR-126 was detected in the DRG from mice that 
received miR-126 compared to those injected with control 
miRNA (Fig.  8b), thus confirming uptake of miR-126 by 
the DRG. Additionally, delivery of miR-126 robustly down-
regulated Dnmt1 and Vegfa mRNA in the DRG (Fig. 8c). 
These results indicate that though the delivery of miR-
126 decreased Dnmt1 and Vegfa expression in the DRG, 
this was not sufficient to reverse nerve injury-induced 
mechanical and thermal hypersensitivity.
Discussion
This study provides evidence indicating that peripheral 
nerve injury induces redistribution of MeCP2 bind-
ing in the DRG. MeCP2 is implicated in pain because of 
Fig. 4 miR-126 locus has enriched MeCP2 binding in SNI model. a MeCP2 peak profile from ChIP-seq at miR-126a/miR-126b shows enrichment of 
MeCP2 binding to miR-126 locus in the SNI model, and virtually no binding in the sham control. b CpG methylation of miR-126 locus was identical 
in SNI and sham control mice. Bisulfite sequencing of the 72-bp sequence of premiR-126 locus harboring 6 CpG sites using DRG genomic DNA 
obtained from SNI and sham control mice showed methylation of all CpG sites in both SNI and sham samples (n = 3). Identical methylation pattern 
in SNI and sham control indicates that SNI does not alter the methylation pattern of premiR-126 locus
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the abnormal thresholds observed in RTT patients [7]. 
Studies assessing the pain threshold of mice with aber-
rant MeCP2 expression, mimicking those observed in 
patients, have shown reduced sensitivity [8–11]. Col-
lectively, these studies indicate that precise regulation of 
MeCP2 levels is crucial for normal pain thresholds. We 
had previously observed an upregulation of MeCP2 in 
the DRG 4 weeks after SNI. DRG neurons have been the 
focus of much research to identify molecular targets of 
pain neurotransmission because they represent primary 
sites for pain processing. Our data show that increased 
MeCP2 expression after peripheral nerve injury can 
induce differential binding of MeCP2 to the genome. This 
may play a crucial role in bringing about either direct or 
indirect global gene-regulatory changes associated with 
chronic pain.
MeCP2 has high affinity for methylated cytosines that 
are followed by a guanine nucleotide (mCG) [1]. MeCP2 
binds broadly throughout the genome in a DNA methyla-
tion-dependent manner. It is now known that MeCP2 can 
bind two alternatively methylated forms of DNA includ-
ing methylated cytosine followed by a nucleotide other 
than guanine (mCH, where H = A, C or T) and hydroxy-
methylcytosine (hmC) [34, 35]. Both mCH and hmC are 
enriched in human and mouse brain, but there are no 
reports to date on the status of these alternately methyl-
ated forms of DNA in the DRG. In general, mCH appears 
to be a repressive mark that inhibits gene expression [35, 
36]. The occurrence of hmC within gene bodies, however, 
has been associated with active gene expression in neu-
rons [34, 36]. Our ChIP-seq data suggest a genome-wide 
shift in the binding pattern of MeCP2 after nerve injury, 
including three thousand distinct mRNA encoding sites. 
There also seems to be redistribution from binding at 
intergenic regions to an overall increase in binding to 
transcriptionally relevant regions and noncoding RNAs. 
MeCP2 quantification in post-mitotic neurons showed 
that it is nearly as abundant as the histone octamer. It 
was suggested that genome-wide binding of MeCP2 in a 
DNA methylation-dependent manner may dampen tran-
scriptional noise and MeCP2 may contribute to the basic 
structure of neuronal chromatin [5]. MeCP2 was shown 
to modulate transcription in a gene-length-dependent 
manner, and preferential upregulation was observed for 
long genes enriched for methylated CpA dinuleotides 
in brain from Mecp2-null mice [16]. Our tag enrich-
ment analyses were more sensitive to binding changes in 
longer genes, simply because statistical power increases 
with tag count, and longer regions (gene bodies) have 
more changes of MeCP2 binding. Hence, our approach 
Fig. 5 miR-126 regulates expression of Dnmt1 and Vegfa in vitro. a Relative expression of endogenous Dnmt1 and Vegfa mRNA in Neuro 2a cells 
transfected with miR-126 Gapdh was used as a normalizer. b Representative Western blot of Dnmt1 and Vegfa using lysate of Neuro 2a cells trans-
fected with miR-126 precursor plasmid for 72 h. Overexpression of miR-126 decreased mRNA and protein levels of Dnmt1 and Vegfa; beta tubulin 
was used as the control. c Immunohistochemistry indicating transfection with miR-126 plasmid co-expressing GFP in Neuro 2a cells decreased 
Dnmt1 levels compared to untransfected cells 72 h post-transfection. Significance determined using unpaired Student’s t test, p value *<0.05, 
***<0.001 (n = 3 for all samples)
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detected stronger binding differences in large genes. 
Thus, binding of MeCP2 at mCG, mCH and hmC along 
with the accompanying alteration in chromatin architec-
ture can collectively play a role in regulating gene expres-
sion in mature neurons.
Neurons in the DRG are surrounded by an enve-
lope of satellite glial cells, and it is well established that 
immune and glial cell responses alter neuronal func-
tion in the  peripheral and central nervous system [37]. 
Our ChIP-seq study was performed using whole DRG, 
and thus, the findings reported here is from a mixed 
cell population. Comparison of cell-specific global DNA 
methylation along with gene expression data will enable 
comparative study to confirm whether methylation-
induced changes in MeCP2 binding resulted in gene 
expression changes. Plasticity of DNA methylation 
was recently investigated in rat DRG 24  h after spinal 
nerve ligation, another peripheral nerve injury model of 
Fig. 6 Expression of miR-126 and its target genes Dnmt1 and Vegfa in the DRG after nerve injury. a Relative expression of miR-126 determined by 
qPCR shows a reduction in miR-126 in SNI model compared to DRG from sham control. U6 was used for normalization (n = 8 sham, n = 7 SNI). b 
Relative expression of Dnmt1 mRNA and c Vegfa transcripts showed an increase in the DRG after nerve injury compared to control (n = 3). Gapdh 
was used as a normalizer. d Representative Western blot and quantification showed an increase of Dnmt1 protein in the DRG after nerve injury. e 
Western blot and quantification showed Vegfa protein was not significantly different in DRG after nerve injury (n = 3 from pooled samples, three 
DRG were pooled for each sample). Significance determined using unpaired Student’s t test, p value *<0.05
Fig. 7 Expression of miR-126 and its target genes Dnmt1 and Vegfa in the DRG from Mecp2-null mouse. a Relative expression of miR-126 in the 
DRG showed comparable expression in Mecp2-null and wild-type littermates. U6 was used for normalization. b Dnmt1 and c Vegfa expression 
was decreased in the DRG from Mecp2-null mouse, indicating MeCP2 has a role in regulating expression of Dnmt1 and Vegfa. Gapdh was used as 
a normalizer. Significance determined using unpaired Student’s t test, p value *<0.05, **<0.01 n = 3 for Mecp2-null (−/y) and wild-type littermate 
mice (+/y)
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neuropathic pain. Though there was widespread remod-
eling of DNA methylation, comparison of genome-wide 
methylation and RNA-seq analysis of promoter regions 
and gene bodies showed that variation of methylation 
was not tightly linked with differences in gene expression 
[38]. The impact of DNA methylation on transcription is 
context dependent because methylation has been shown 
to either inhibit or promote gene expression, depend-
ing on the location of the mark [39]. MeCP2 is an abun-
dantly expressed protein that seems to bind throughout 
the genome, and therefore, it is plausible that in addition 
to regulating specific target genes, MeCP2 may broadly 
affect genome-wide transcription.
MeCP2 alters gene expression through several mecha-
nisms, but MeCP2 function itself is regulated by miRNAs 
and several posttranslational modifications including 
activity-dependent phosphorylation [40]. MeCP2 also 
suppress miRNA biogenesis by directly binding to 
DiGeorge syndrome critical region 8 (DGCR8), a critical 
component of the nuclear miRNA-processing machinery 
[41]. MeCP2-bound sequence tags indicated that miRNA 
regions were enriched for MeCP2 binding in the SNI 
model compared to sham control. It has been proposed 
that the functions of miRNAs are more pronounced 
under stress or disease states [42], and alterations in 
MeCP2 binding could be one of the mechanisms contrib-
uting changes in miRNA expression.
To investigate the impact of nerve injury-induced redis-
tribution, we studied miR-126, the miRNA with high-
est enrichment for MeCP2 binding post-nerve injury. 
miR-126 is encoded within the intron of Egfl7 and highly 
expressed in brain [43]. A recent study demonstrated a 
role for miR-126 in reducing inflammation and improv-
ing the functional deficit after spinal cord injury. miR-126 
decrease promoted angiogenesis and inflammation in the 
spinal cord after a weight induced contusion and admin-
istration of miR-126 reduced locomotor deficit and tis-
sue damage [44]. We have previously observed a decrease 
in miR-126 in L4 and L5 DRG in rats 4 weeks after spi-
nal nerve ligation [45]. Hsa-miR-126 was downregulat-
ing in whole blood from patients with complex regional 
pain syndrome compared to healthy donors [46] and in 
Fig. 8 Administration of exogenous miR-126 decreased Dnmt1 and Vegfa expression in vivo but did not alter pain sensitivity. a Mechanical sensitiv-
ity measured by von Frey filaments showed that intrathecal delivery of miR-126 did not alter the paw withdrawal threshold in SNI model mice. 
Arrows indicate daily intrathecal injections with 2 nmol miR-126 or control miRNA via catheter (n = 5 for miR-126 and miR-control injected mice, 
n = 3 for PBS injected mice). b Confirmation of miR-126 delivery to DRG. A qPCR performed using DRG collected from mice injected with miR-126 
or control miRNA showed an increase in miR-126 in mice that received miR-126 compared to miR-control injected mice indicating successful deliv-
ery. c Relative expression of Dnmt1 and Vegfa mRNA in the DRG of miR-126 and control injected mice. Increased miR-126 decreased the expression 
of endogenous Dnmt1 and Vegfa compared to miR-control injected mice. Significance determined using unpaired Student’s t test, p value, **<0.01, 
***<0.001 (n = 5 for miR-126 and miR-control injected mice, n = 3 for PBS injected mice). d Schematic representation of nerve injury-induced 
alterations of MeCP2 and downstream gene expression changes. SNI induced enriched binding of MeCP2 to miR-126 locus resulting in repression 
of miR-126. Lower miR-126 leads to increased expression of its two target genes Vegfa and Dnmt1. Vegfa could contribute to the progression of 
pain pathology by modulating angiogenesis and neuro-inflammation. Dnmt1 propagate established methylation patterns during cellular division 
by recognizing and copying parent strand methylation at symmetrical CG dinucleotides to the newly synthesized daughter strand and its increase 
after SNI can alter or maintain methylation, and may contribute to gene expression changes ensuing SNI
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exosomes from CRPS patients compared to that of con-
trol [47]. Nerve injury induced upregulation of MeCP2 
and a decrease in miR-126 in mice after SNI. There was 
no MeCP2 binding at the miR-126 locus in sham control 
mice. Furthermore, Mecp2-null mice and their wild-type 
littermates have similar levels of miR-126. This indicates 
that nerve injury induces the enriched binding of MeCP2 
to miR-126 locus, resulting in miR-126 repression. We 
also observed increased expression of Vegfa and Dnmt1 
in the SNI model. Dnmt1 and Vegfa are two validated tar-
get genes of miR-126 [31, 32]. Both genes are implicated 
to have a role in peripheral pain mechanisms. Dnmt1 is 
necessary for maintenance methylation, gene regula-
tion, and chromatin stability [48]. Dnmt1 mutations in 
humans contribute to hereditary sensory neuropathy 
[49] and autonomic neuropathy [50]. Our current study 
and others have shown upregulation of Dnmt1 in the 
DRG after peripheral nerve injury [51]. Vegfa regulates 
angiogenesis in both development and various patholo-
gies [52]. In the chronic constriction injury model of neu-
ropathic pain, Vegfa and its receptor was upregulated in 
the DRG, and addition of anti-Vegf antibody increased 
thermal and mechanical withdrawal latency [53]. We 
observed increased Vegfa mRNA in the DRG after SNI. 
miR-126 regulation of these targets is further supported 
by our molecular studies. Mecp2-null mice had reduced 
levels of Dnmt1 and Vegfa. Reduced transcript levels in 
Mecp2-null mice can be interpreted as MeCP2 having a 
role in activation of these genes. Since we did not observe 
a significant binding of MeCP2 to Dnmt1 and Vegfa, one 
of the indirect mechanisms contributing to their upreg-
ulation after SNI could be the repression of miR-126 by 
MeCP2.
DNA methylation is a stable epigenetic modification. 
Since SNI and sham DRG had an identical methylation 
pattern at miR-126 locus, increased binding of MeCP2 
to miR-126 can be considered to be independent of the 
methylation status, but dependent on nerve injury. Likely, 
nerve injury changes the chromatin architecture, allow-
ing increased access for MeCP2 to bind miR-126 locus. 
Further studies are needed to explore the role of MeCP2 
in altering chromatin availability.
Administration of miR-126 did not alter the pain 
threshold in mice after SNI, and this could be due to the 
severity of nerve injury used to generate chronic neuro-
pathic pain in the SNI model. miRNAs are fine tuners of 
gene expression, and the low pain threshold generated 
by SNI could have been too severe for a single miRNA 
to reverse. Acting as a rheostat, the influence of miR-
NAs is often described as modest. As was reported for 
the studies in a spinal cord injury model [44], the role of 
miR-126 in reversing inflammation and functional defi-
cits could not be captured in the evoked pain behavioral 
assessments we employed. Future studies in less severe 
nerve injury or inflammatory pain models that may cap-
ture the involvement of Vegfa should be explored. Several 
miRNAs showed changes in MeCP2 binding after SNI. 
Administering these miRNAs, either individually or as a 
cocktail of several miRNAs, to regulate a larger number 
of downstream target genes, could potentially be benefi-
cial in conferring analgesic effects.
Conclusions
Decreased pain perception in children with RTT sug-
gests that MeCP2 function is important in modulating 
pain. Our ChIP-seq analysis to determine the functional 
implication of increased MeCP2 in the DRG after nerve 
injury showed redistribution, and enrichment within 
transcribed regions in the SNI model compared to sham 
control. For miRNA regions, enriched binding was 
detected only in sham or SNI, indicating different regu-
latory profiles in SNI versus sham DRG. Distinct bind-
ing patterns of MeCP2 in SNI could therefore mediate 
gene expression changes following nerve injury. Enriched 
MeCP2 binding to miR-126 locus after nerve injury 
repressed miR-126 expression, and this was not medi-
ated by alterations in methylation pattern at the miR-126 
locus. Downregulation of miR-126 resulted in the upreg-
ulation of its two target genes Dnmt1 and Vegfa. These 
target genes were significantly downregulated in Mecp2-
null mice compared to wild-type littermates, indicating a 
regulatory role for MeCP2 in activating Dnmt1 and Vegfa 
expression. Intrathecal delivery of miR-126 decreased 
Dnmt1 and Vegfa expression in the DRG, but was not 
sufficient to reverse nerve injury-induced mechanical 
and thermal hypersensitivity. Collectively, these studies 
show that MeCP2 broadly binds chromatin and there-
fore can influence numerous downstream targets. The 
findings from this study provide the molecular basis for 
a better understanding of how epigenetic changes induce 
alterations in gene expression that occur in the DRG after 
nerve injury.
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